Immunovia Strengthens Management Team Ahead of its Commercial Launch of IMMray™ PanCan-d
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, today announced the strengthening of the Company’s management team with two very experienced executives. Hans Christian Pedersen has been appointed Vice-President of Business Development, succeeding Henrik Winther, and Dr. Peter Schultz-Knappe has been appointed Chief Technology Officer (CTO).
Henrik Winther, Senior Vice-President of Business Development, is stepping down from his position to pursue another opportunity and will remain with the company until the end of December to ensure a smooth transition.
“We are tremendously excited to welcome Hans Christian and Peter, two deeply experienced executives as we prepare for a solid commercial launch of IMMray™ PanCan-d. Immunovia continues to ramp up its commercialization of IMMray™ PanCan-d, as well as increasing the focus on the pipeline opportunities in autoimmunity and lung cancer” said Mats Grahn, CEO of Immunovia. “Each incoming leader’s unique set of skills, coupled with their vast experience from several successful companies, makes me confident that we now have exactly the right leadership team in place to push the company into our next phase of growth. I would also like to thank Henrik Winther for his diligent work in helping us bring Immunovia to where we are today.”
Hans Christian Pedersen joins Immunovia from Unilabs, where he was the Director of Business Development of Companion diagnostics and Pharma Services. He brings over 16 years of industry experience working with companion diagnostics development, marketing and scientific affairs. Prior to his time with Unilabs, he was the Director of Scientific Affairs, Global Marketing at Agilent Technologies. Mr. Pedersen has held multiple positions at Agilent Technologies and previously at Dako. He received his Masters’ Degree in Biology from University of Copenhagen.
Peter Schultz-Knappe joins Immunovia from Protagen AG, Germany, where he was a Board Member and CSO. He brings over 30 years of Biotech experience and has focused much of his extensive global expertise in the development, manufacturing and commercialization of modern multiplex diagnostic tools. While he was at Protagen, his day-to-day responsibilities included managing Protagen’s R&D. This included the building of Protagen’s commercial and clinical key opinion leader networks with a focus on the autoimmune disease area.
Dr. Schultz-Knappe received his master’s and PhD from the Ruprecht-Karls-Universität Heidelberg in the field of human medicine.
For more information, please contact:
Director of Investor Relations
Tel: +46 7 93 486 277
This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:00 CET on December 5, 2019.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.